Andrew N. Fleischman

Chrysalis BioTherapeutics (United States)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property”.

Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property

Expert Opinion on Therapeutic Patents(2021)10.1080/13543776.2022.1994945

N/A

0DataRank · unranked

22 citations

Aref Rastegar, Osheiza Abdulmalik, Abdelsattar M. Omar, Yan Zhang, Andrew N. Fleischman +2 more

The Penn State Protein Ladder system for inexpensive protein molecular weight markers

Scientific Reports(2021)10.1038/s41598-021-96051-x

N/A

0DataRank · unranked

2 citations

John Williamson, Yoshitaka SHIBATA, Rosalie P. Sowers, Andrew N. Fleischman, Song Tan +1 more